Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125358101 | 12535810 | 1 | I | 20160629 | 20160707 | 20160707 | EXP | CA-ASTRAZENECA-2016SE71362 | ASTRAZENECA | 36.00 | YR | Y | 0.00000 | 20160707 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125358101 | 12535810 | 1 | PS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 550.0MG UNKNOWN | U | U | 22047 | 550 | MG | PROLONGED-RELEASE TABLET | |||||
| 125358101 | 12535810 | 2 | C | CARDURA | DOXAZOSIN MESYLATE | 1 | 0 | TABLET | |||||||||||
| 125358101 | 12535810 | 3 | C | DEXILANT | DEXLANSOPRAZOLE | 1 | 0 | CAPSULE | |||||||||||
| 125358101 | 12535810 | 4 | C | REMERON RD | MIRTAZAPINE | 1 | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125358101 | 12535810 | 1 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125358101 | 12535810 | DS |
| 125358101 | 12535810 | HO |
| 125358101 | 12535810 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125358101 | 12535810 | Diabetes mellitus | |
| 125358101 | 12535810 | Pancreatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |